UNITED STATES SECURITY AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 __________  FORM 10-K/A (Amendment No. 2) __________  (MARK ONE)  ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934  For the fiscal year ended September 30, 2018  or  ☐TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934  For the transition period from _________
to _________  Commission File Number: 333-170315    AngioSoma, Inc. (Exact name of registrant as specified in its
charter)  Nevada
    
    27-3480481(State or other jurisdiction of Incorporation or organization)
    
    (I.R.S. Employer Identification Number)2500 Wilcrest Drive, 3rd FloorHouston, TX
    
    77042(Address of principal executive offices)
    
    (Zip code)  Registrant’s telephone number, including
area code: 832-781-8521  Securities registered pursuant to Section
12(g) of the Act:  Title of Each Class
    
    Name of Each Exchange on which RegisteredCommon stock, $0.001 par value
    
    OTC Markets    EXPLANATORY NOTE



This Amendment No. 2 on Form 10-K/A (this “Amendment”) amends our Annual Reports on Form 10-K
for the year ended September 30, 2018, originally filed with the Securities and Exchange Commission (“SEC”) on January
3, 2019 (the “Original Report”) inadvertently included incorrect disclosure in footnote number 3 under ITEM 12.
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS beginning on page 47 of our
previously filed 10-K that states “Effective January 25, 2017, Ms. Blankenship transferred voting control of the Series E
Preferred stock to Mr. David P. Summers.” The quoted statement should have been deleted because effective May 16, 2017 the
Certificate of Designation was amended to prohibit shared voting. As a result, the transfer of voting control was ineffective as
of May 16, 2017.



Footnote 3 under ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED
STOCKHOLDER MATTERS is corrected to read: “Ms. Blankenship owns 1,000,000 shares of the Company’s Series E Preferred
Stock. The Series E Preferred Stock carries two votes for each outstanding share of the Company’s common stock and, as a
result, has 2/3 voting control over any shareholder votes.”



Because these changes do not include changes to the financial statements included in the Original Report,
we are not filing a new consent of our auditors with this Amendment. In connection with the filing of this Amendment and pursuant
to the requirements of Rule 12b-15 under the Securities Exchange Act of 1934, as amended, we are including with this Amendment
new certifications of our principal executive officer and principal financial officer.



Except as described above, no other changes have been made to the Original Report. The Original Report continues
to speak as of the date of the Original Report, and we have not updated the disclosures contained therein to reflect any events
that have occurred at a date subsequent to the filing of the Original Report. Material events may have occurred subsequent to the
filing of the Original Report that are not reflected in this Amendment.





PART IV

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

3.1Amendment to Certificate of Designation Series E Preferred Stock filed May 16, 2017 (1)3.2Certificate of Correction to Amendment to Certificate of Designation filed February 14, 2018 (1)31.1Rule 13(a)-14(a)/15(d)-14(a) Certification of principal executive officer and principal financial and accounting officer. (1)32.1Section 1350 Certification of principal executive officer and principal financial and accounting officer. (1)__________
(1)Filed herewith


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report
to be signed on its behalf by the undersigned thereunto duly authorized.

AngioSoma, Inc.Date: August 16, 2019BY: /s/ Alex BlankenshipAlex BlankenshipChief Executive Officer, President, Secretary, Treasurer, Principal Executive Officer, Principal Financial and Accounting Officer and Director

- 2 -